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Objectives This study evaluated the use of an injectable hydrogel derived from ventricular extracellular matrix (ECM) for
treating myocardial infarction (MI) and its ability to be delivered percutaneously.
Background Injectable materials offer promising alternatives to treat MI. Although most of the examined materials have
shown preserved or improved cardiac function in small animal models, none have been specifically designed for
the heart, and few have translated to catheter delivery in large animal models.
Methods We have developed a myocardial-specific hydrogel, derived from decellularized ventricular ECM, which self-
assembles when injected in vivo. Female Sprague-Dawley rats underwent ischemia reperfusion followed by injec-
tion of the hydrogel or saline 2 weeks later. The implantation response was assessed via histology and immuno-
histochemistry, and the potential for arrhythmogenesis was examined using programmed electrical stimulation
1 week post-injection. Cardiac function was analyzed with magnetic resonance imaging 1 week pre-injection and
4 weeks post-MI. In a porcine model, we delivered the hydrogel using the NOGA-guided MyoStar catheter (Biolog-
ics Delivery Systems, Irwindale, California), and utilized histology to assess retention of the material.
Results We demonstrate that injection of the material in the rat MI model increases endogenous cardiomyocytes in the
infarct area and maintains cardiac function without inducing arrhythmias. Furthermore, we demonstrate feasibil-
ity of transendocardial catheter injection in a porcine model.
Conclusions To our knowledge, this is the first in situ gelling material to be delivered via transendocardial injection in a large ani-
mal model, a critical step towards the translation of injectable materials for treating MI in humans. Our results war-
rant further study of this material in a large animal model of MI and suggest this may be a promising new therapy for
treating MI. (J Am Coll Cardiol 2012;59:751–63) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.888e
a
tCardiovascular disease continues to be the leading cause of death
in the United States, as well as the rest of the western world, with
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2011, accepted October 28, 2011.an estimated 785,000 newmyocardial infarctions (MIs) each year
(1). Post-MI pathological changes are often progressive, consist-
ing of an initial inflammatory phase, followed by the up-regulation
of matrix metalloproteinases that degrade the extracellular matrix
(ECM), leading to infarct expansion and wall thinning, and
eventual collagen scar deposition to resist deformation and rup-
ture. The resultant negative left ventricular (LV) remodeling is
thought to independently contribute to progressive deterioration
of cardiac function leading to heart failure post-MI (2). When
nd-stage failure occurs, heart transplantation or implantation of
n LV assist device are the only available treatments. Therefore,
he development of new therapies is necessary.
One of the first alternatives to heart transplantation was aechnique termed cellular cardiomyoplasty. This technique con-
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Cardiac ECM Hydrogel for Treating MI February 21, 2012:751–63sists of injecting cells, suspended in
saline or cell culture medium, into
the recipient’s myocardium (3–9).
This is an attractive approach be-
cause it allows forminimally invasive
intramyocardial delivery through a
catheter. Althoughmany clinical tri-
als using cellular cardiomyoplasty
have shown some promise (3,6–9),
cell retention, engraftment, and sur-
vival have been difficult to achieve,
due in part to the lack of an appro-
priate extracellular microenviron-
ment (10). Thus, approaches using
cardiac tissue engineering have be-
gun utilizing synthetic and natural
biomaterials as scaffolds to improve
transplanted cell survival (11), or as
stand-alone acellular scaffolds to re-
place the degraded cardiac ECM,
preserve or improve cardiac func-
tion, and attenuate LV remodeling
(12–15). Injectable biomaterials are
particularly attractive since they have
the potential to be delivered using a
minimally invasive approach, and a
aterial-only therapy would eliminate many of the complications
ssociated with cell therapies.
We have developed a myocardial matrix hydrogel, derived
rom decellularized ventricular porcine ECM, which is the
rst cardiac-specific injectable material, offering a replace-
ent scaffold that mimics the native cardiac extracellular
nvironment (16). The myocardium was first decellularized
sing a perfusion-based technique to generate an intact
-dimensional scaffold (17). In contrast, we process the
entricular ECM into an injectable liquid that self-
ssembles upon injection in vivo to form a nanofibrous and
orous scaffold. This material offers a biochemical and
tructural composition that mimics the native ventricular
CM. Herein, we tested the safety and efficacy of injecting
he myocardial matrix hydrogel in a rat myocardial infarc-
ion model. We demonstrate that injection of myocardial
atrix increases endogenous cardiomyocytes in the in-
arct area and preserves cardiac function post-MI, with-
ut increasing incidences of arrhythmia. Considering that
any biomaterials being explored as cardiac therapies in
mall animal models do not have the appropriate prop-
rties to translate to catheter delivery in the heart (18), we
lso tested the ability of the myocardial matrix hydrogel
o be delivered via catheter in a porcine model. We
emonstrate that the myocardial matrix can be delivered
o the myocardium via a percutaneous transendocardial
pproach, thus paving the way towards clinical translation
f a new minimally invasive, biomaterial-based therapy
Abbreviations
and Acronyms
ECG  electrocardiogram
ECM  extracellular matrix
ED  end-diastole
EDV  end-diastolic volume
EF  ejection fraction
ES  end-systole
ESV  end-systolic volume
H&E  hematoxylin
and eosin
IHC 
immunohistochemistry
LC-MS/MS  liquid
chromatography mass
spectrometry
LV  left ventricle
MI  myocardial infarction
MRI  magnetic resonance
imaging
SDS  sodium dodecyl
sulfate
VT  ventricular
tachycardiaor MI. wethods
yocardial matrix preparation. The myocardial matrix
as decellularized and prepared as previously described (16).
Briefly, Yorkshire farm pigs (35 to 45 kg) were euthanized
using an overdose of pentobarbital (90 mg/kg) administered
intravenously, and their hearts were then removed. The
ventricular tissue was isolated and cut into small rectangular
pieces, rinsed in phosphate-buffered saline, and decellular-
ized using 1% sodium dodecyl sulfate (SDS), until the
ECM was white. Following completed decellularization,
prior to lyophilization, aliquots of the decellularized ECM
was then rinsed with deionized water overnight, lyophilized,
and milled into a fine powder. Following complete decel-
lularization, prior to lyophilization, aliquots of decellular-
ized ECM were fresh frozen in Tissue-Tek OCT com-
pound (Sakura Finetek, Torrence, California), sectioned into 5
m slices, and stained with hematoxylin and eosin (H&E)
stain to confirm decellularization. The ECM powder was
solubilized by enzymatic digestion using pepsin and 0.1
mol/l HCl for at least 54 h prior to use, as modified from a
previously published protocol (19). The liquid myocardial
matrix was adjusted to pH 7.4 with NaOH, on ice, and
brought to 6 mg/ml for injection. A Blyscan sulfated
glycosaminoglycan assay (Biocolor, Carrickfergus, United
Kingdom) was used to confirm sulfated glycosaminoglycan
content (16). For catheter compatibility tests in the porcine
model and for identification at 1 week post-injection in the
rat model, the material was biotin labeled. For biotin
labeling, a 10 mmol/l solution of EZ link Sulfo-NHS-
Biotin (Pierce, Rockford, Illinois) was prepared and mixed
with the liquid myocardial matrix for a final concentration
of 0.3 mg biotin/1 mg matrix. The mixture was allowed to
sit on ice for 2 h prior to use.
Liquid chromatography mass spectrometry. Liquid chro-
matography mass spectrometry (LC-MS/MS) was used to
analyze the myocardial matrix, to ensure retained protein
content. Lyophilized powder samples were digested in
trypsin, in preparation for LC-MS/MS. Electrospray ion-
ization experiments were run on a QSTAR-Elite hybrid
mass spectrometer (AB/MDS Sciex, Foster City, Califor-
nia) interfaced to a reversed-phase high-pressure liquid
chromatograph. The column used was a 10 cm  180 ID
glass capillary packed with 5-m C18 Zorbax beads (Agi-
ent Technologies, Santa Clara, California). Peptides were
luted from the C18 column into the mass spectrometer
sing a linear gradient of 5% to 80% Buffer B (100%
cetonitrile, 0.2% formic acid, and 0.005% trifluoroacetic
cid) over 60 min at 400 l/min. (Buffer A was composed of
8% H2O, 2% acetonitrile, 0.2% formic acid, and 0.005%
rifluoroacetic acid). LC-MS/MS data were acquired in a
ata-dependent fashion, time-of-flight MS were acquired at
/z 400 to 1,600 Da, and MS/MS data were acquired from
/z 50 to 2,000 Da. Once collected, peptide identifications
ere based on at least 1 peptide with the confidence of
753JACC Vol. 59, No. 8, 2012 Singelyn et al.
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Pilot 2.0 (Life Technologies, Carlsbad, California).
Rat MI and injection surgical procedures. All experi-
ments in this study were performed in accordance with the
guidelines established by the Committee on Animal Re-
search at the University of California, San Diego, and the
American Association for Accreditation of Laboratory An-
imal Care. Animal numbers used in each experimental
subset are reported in Table 1. MI was induced via 25-min
ischemia-reperfusion surgery on female Sprague Dawley
rats (225 to 250 g). Animals were anesthetized with 5%
isoflurane, intubated, and maintained at 2.5% isoflurane. A
left thoracotomy (20) was performed to allow access to the
heart, the pericardial sac removed, and a single 6-0 silk
suture was placed into the myocardium, around the left
coronary artery. The 6-0 suture was tied in a loop, knotted
at the end of the loop, a 3-0 silk suture was tied over the
knot, and then the 3-0 suture was pulled through the 6-inch
PE90 tubing to occlude the artery for 25 min. Ischemia-
reperfusion for as little as 17 min with this method of
occlusion has been shown to cause consistent infarcts
(21,22). After 25 min, the tubing was released, and the
suture was removed, allowing the vessel to reperfuse. The
animal was then sutured and allowed to recover. Two weeks
post-MI, rats were randomized to ensure a similar distribu-
tion of ejection fraction (EF) in each group based on
baseline magnetic resonance imaging (MRI) measurements,
and injected with 75 l of either saline or solubilized
myocardial matrix at 6 mg/ml following a procedure previ-
ously described (13,16,22). Briefly, an incision was made in
the abdomen, and the diaphragm was cut to expose the
heart. A single injection of material was delivered through a
30-gauge needle into the LV wall, and was confirmed by a
lightening of the tissue. After injection, the abdomen was
stitched closed after suction of the chest cavity, and animals
were allowed to recover. For both surgical procedures,
animals were given 0.05 mg/kg of buprenorphine hydro-
chloride (Reckitt Benckiser Healthcare [UK], Hull, United
Kingdom), an analgesic, prior to recovery from anesthesia.
Animals were also given 3 ml of lactated Ringers (Hospira,
Lake Forest, Illinois) solution for hydration during surgery.
Programmed electrical stimulation. To test arrhythmia
inducibility, programmed electrical stimulation was per-
formed on hearts, 1 week post-injection. Rats were anes-
thetized, as previously described, and surgical access to the
heart was gained. A pacing electrode was inserted gently
into the viable region of the LV wall, such that the exposed
Animal NumbersTable 1 Animal Numbers
Saline Matrix
Arrhythmia inducibility, rat 16 20
Histology and IHC, rat 5 5
Functional assessment, rat 6 6
Catheter delivery, pig 2IHC  immunohistochemistry.electrode tip came in contact with the interior of the LV
wall, and the necessary voltage was determined, using a fixed
rate pacing (pulse width of 1 ms, cycle length of 120 ms),
which was increased until pacing was induced, and voltage
was then doubled for the rest of the pacing protocol. The
electrocardiogram (ECG) was recorded throughout the
pacing procedure, using an ECG signal recorder (DATAQ
di-148, DATAQ Instruments, Akron, Ohio), for 1 full
hour. Burst pacing and extra-stimulus testing were induced,
according to methods previously developed (23–25). After
each pacing test, the ECG was observed for any induced
arrhythmias; incidences of ventricular tachycardia (VT)
were recorded. At the end of the entire burst pacing and
extra-stimulus pacing procedures for the rat, the ECG
recording was stopped and saved. The heart was excised and
fresh frozen for histological analysis.
Magnetic resonance imaging. Cine-MRI was performed
on a 7-T Bruker magnet, at the UC San Diego fMRI
center, using an ECG-triggered fast low-angle shot
(FLASH) gradient echo pulse sequence. The following
parameters were used: flip angle  15°, echo time  1.28
ms, repetition time  7.7 ms, data matrix  256  128,
field of view  50 mm2, slice thickness  1 mm, and 25
phases were collected per cardiac cycle. Scanning parameters
and methods were modified from those determined effective
to evaluate ventricular geometry in murine models (26–28).
Briefly, rats were anesthetized with isoflurane, while mon-
itoring heart rate and respiratory rate. The long axis of the
heart was identified, and subsequent contiguous short-axis
slices were acquired throughout the cardiac cycle from apex
of the heart to the base of the heart. Images were acquired
using a gating system, so that the first image corresponds to
end-diastole (ED). Image J (NIH, Bethesda, Maryland) was
used to manually outline the endocardial surface for each
slice corresponding to ED and end-systole (ES), for the
calculation of ventricular area. Although true ES occurs
upon opening of the mitral valve and can be detected in
echocardiography images (29), for consistency of image
analysis, ES is identified as minimal LV lumen area. Each
area was then multiplied by slice thickness (1 mm) to
calculate LV volume. End-diastolic volume (EDV) and
end-systolic volume (ESV) were calculated, allowing for the
calculation of EF. From the volume obtained at ED and
ES, EF (%) was calculated to be: ([EDV  ESV]/EDV) 
100%. At 1-week post-MI, MR images were taken for
evaluation of baseline pre-injection parameters. At 6 weeks
post-MI (4 weeks post-injection), hearts were again as-
sessed as described in earlier text. EF and LV geometry were
compared pre- and post-injection therapy, thus allowing
each animal to serve as its own internal control. Healthy
animals were also imaged, revealing an EF of 74  5% for
our model. Rats that did not present an EF representative of
an infarct (69%, 1 standard deviation from a healthy
animal) at 1 week were eliminated from the study.
Catheter delivery in a porcine model. Biotin-labeled
myocardial matrix was tested for clinical feasibility within a
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device for transendocardial delivery, as developed for min-
imally invasive cellular transplantation (4,5). Two Yucatan
mini pigs (28 to 40 kg) were used for the study. For 1
animal, pre-anesthesia, Telazol (5 mg/kg, tiletamine HCl
and zolazepam HCl, Fort Dodge Animal Health, Fort
Dodge, Iowa) was administered, followed by the anesthetic
propofol (2.4 mg/kg), until effect, and atrophine (0.02
mg/kg). The animal was intubated, and ventilated with 1%
to 2.5% isoflurane and 1 l/min oxygen. An 8-F arterial
sheath was inserted through the right femoral artery for
access to the LV. Coronary angiography was performed for
visualization of the arteries, and the ECG was monitored
throughout the surgery. Myocardial matrix was biotin la-
beled prior to injection for histological post-operative iden-
tification, and kept on ice until time of injection. Prior to
injection, a unipolar electromechanical map (NOGA) was
created of the endocardial wall and used to guide injection.
The injection, through a 27-gauge retractable needle, fol-
lowed protocols commonly used for cellular delivery (4,5,9).
Here, a 1-ml Luer lock syringe was loaded with myocardial
matrix and attached to the MyoStar catheter for transendo-
cardial injection. The NOGA map was used for identifica-
tion of injection locations, and 25 0.2-ml injections were
performed throughout the LV free wall and septal wall. In
the second animal, following anesthesia, an MI was given
via deployment of 2 embolization coils as previously de-
scribed (5,30). Two weeks later, an injection procedure was
performed with the NOGA-guided MyoStar catheter as
described earlier in the text. Fifteen 0.25-ml injections were
performed in the infarct and border zone.
Histology and immunohistochemistry. For the rat stud-
ies, animals were euthanized with an overdose of sodium
pentobarbital (200 mg/kg). Hearts were immediately re-
moved, fresh frozen in Tissue Tek OCT freezing medium,
and sectioned into 10-m slices. Slides spaced approxi-
ately every 0.5 mm were stained with H&E for identifi-
ation of infarcted tissue or for examination of inflammatory
esponse by a pathologist blinded to the study. Immunohis-
ochemistry (IHC) was performed on 5 slides from the
nfarct in each heart using the antibodies directed against
he following antigens: Ki67 (Abcam, Cambridge, Massa-
husetts; 1:100), cardiac-specific troponin T (NeoMarkers,
remont, California; 1:50), Connexin43 (Millipore, Te-
ecula, California; 1:200), alpha smooth muscle actin
Dako, Carpinteria, California; 1:75), anti-CD163 (AbD
erotec, Raleigh, North Carolina; 1:50), and anti-c-Kit
Santa Cruz Biotechnology, Santa Cruz, California; 1:100).
ll primary antibodies were visualized by the addition of
lexa Fluor 568 and 488 (Invitrogen, Carlsbad, California)
econdary antibodies. Sections that were stained with only
he primary antibody or only the secondary antibody were
sed as negative controls. Sections were stained with
oechst to visualize nuclei, and mounted with Fluoro-
ount (Sigma, St. Louis, Missouri). Images were taken
ith a Carl Zeiss Observer D.1 (Carl Zeiss, Oberkochen,ermany) and analysis was performed by a blinded inves-
igator with AxioVision software (Carl Zeiss) and Photo-
hop (Adobe Systems, San Jose, California). To assess
etention and biodistribution of the myocardial matrix upon
njection in a porcine model, the heart and satellite organs
ere removed for histological analysis. The pigs remained
n anesthesia for 1 to 2 h following the injection surgery,
efore being euthanized with Fatal-Plus Solution (Vortech
harmaceuticals, Dearborn, Michigan) at 0.22 ml/kg. This
ime frame was determined in the rat model to be adequate
ime to allow for gelation of the material within the
yocardial tissue (16). Upon sacrifice, the heart was re-
oved, with pericardium intact. Heart slices were fresh
rozen using Tissue-Tek OCT compound for histological
nalysis, to locate the myocardial matrix. Five to 10 g of
ach of the following organs were collected to assess
istribution to satellite organs as previously described for
ell retention following catheter delivery (5,31): right and
eft lungs, liver, spleen, right and left kidneys, and right and
eft brain. Samples were frozen for histological analysis. The
entricular tissue and satellite organs were each sectioned
nto 10-m sections and stained with H&E. Adjacent
ections were stained for visualization of biotin-labeled
yocardial matrix. Slides were fixed in acetone for 1.5 min,
ncubated with superblock buffer (30 min), followed by 3%
ydrogen peroxide (30 min), and horseradish peroxidase–
onjugated neutravidin (5 g/ml, 30 min) at room temper-
ature. The reaction was visualized by incubation with
diaminobenzidine for 10 min. Sections from each organ
were stained at the same time as the ventricular tissue, and
images taken after 10 min of incubation.
Statistical analysis. Data are presented as mean  stan-
dard error of the mean. MRI data pre- and post-treatment
were assessed for each group using a paired t test. Changes
in EF, ESV, and EDV, and IHC data were compared with
a 2-sample t test. Significance was accepted at p  0.05.
Results
Injectable myocardial matrix fabrication and characterization.
We isolated ventricular ECM from fresh porcine ventricular
myocardium (Fig. 1A) using SDS as previously described
(16). After approximately 4 to 5 days in 1% SDS, cellular
material was effectively removed, yielding white, translucent
ventricular ECM (Fig. 1B). H&E sections of the decellular-
ized ECM confirmed cell removal and lack of nuclei (Fig. 1C).
The cardiac ECM was then lyophilized and milled into a
powder (Fig. 1D), and finally solubilized with enzymatic
digestion (Fig. 1E), thereby allowing for injection in sub-
sequent studies (Fig. 1F).
To confirm the decellularized myocardial ECM retained
the proteins and proteoglycans native to the myocardium,
myocardial matrix powder was characterized using LC-MS/
MS. LC-MS/MS revealed a variety of ECM proteins,
indicating retained protein content after decellularization.
The ECM proteins, glycoproteins, and proteoglycans iden-
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February 21, 2012:751–63 Cardiac ECM Hydrogel for Treating MItified included: collagen types I, III, IV, V, and VI, elastin,
fibrinogen, lumican, perlecan, fibulin, and laminin. Colla-
gen, laminin, and elastin are the major ECM proteins,
responsible for structure. Perlecan, a heparin sulfate pro-
teoglycan associated with vascularized tissues, is known to
promote adhesion and basic fibroblast growth factor recep-
tor binding, as well as plays a role in developmental and
remodeling processes, such as angiogenesis (32–34). Fibu-
lin, a calcium-binding glycoprotein, commonly associates
with other ECM components such as fibronectin (35,36).
he identification of these components within the decellu-
arized and processed myocardial matrix indicates a retained
omplex combination of proteins and proteoglycans, impor-
ant for a biomimetic tissue engineering scaffold. It should,
owever, be noted that mass spectrometry is not an all-
nclusive technique, and therefore, other proteins may not
ave been identified.
rrhythmia inducibility. Numerous materials have been
njected into infarcted rodent myocardium to date, yet no
tudies have directly assessed safety in terms of a potential
or arrhythmias, which has been a concern with cell injec-
ions (3,37–39). We therefore assessed arrhythmia induc-
bility using programmed electrical stimulation in vivo by
urst and extrastimulus pacing protocols in rats 1 week
ost-injection of myocardial matrix (n  20) compared to
aline (n  16). We chose to examine 1 week post-injection
Figure 1 Myocardial Matrix Fabrication
(A) Porcine ventricular myocardium is sliced and then (B) decellularized using sod
reveals cellular removal. The decellularized extracellular matrix is then milled into
for injection via syringe and a 27-gauge needle (F).because the material is still present in the tissue at this time.In vivo pacing protocols (23–25) induced nonsustained VT
(monomorphic or polymorphic, self-terminating VT) in
37.5% of saline-injected hearts and 35% of matrix-injected
hearts. Sustained VT (30 s) was induced once during burst
pacing in a matrix-injected rat (5% occurrence rate), and
once during extrastimulus pacing in a saline-injected rat
(6.25% occurrence rate). No statistical significance was
found when comparing the average incidence of VT be-
tween groups (p  0.8) (Fig. 2).
Histological and immunohistochemical analysis. To ex-
amine the local tissue response to myocardial matrix injec-
tion, a subset of animals utilized in the arrhythmia studies
were utilized for histological and immunohistochemical
analysis (n  5 each group). Histological assessment of
infarcts 1 week post-injection showed an increased cellular
infiltration response in myocardial matrix injection animals.
There was a moderate mononuclear cell infiltration response
with predominantly lymphocytes and some macrophages
(Fig. 3A). Additional spindle-shaped cells were also ob-
served, likely indicating some fibroblast infiltration. There
was no indication of matrix encapsulation or rejection. We
further performed IHC on the heart sections with antibod-
ies for markers for cardiomyocytes (troponin), M2 macro-
phages (CD163), and proliferative cells (Ki67). Striking
differences were observed in the size of cardiomyocyte
islands surviving within the infarct region in matrix-injected
decyl sulfate. (C) Hematoxylin and eosin staining of a histological section
powder (D) and then solubilized through enzymatic digestion (E), which allowsium do
a finehearts, and we thus quantified the area of these regions
a
h
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Cardiac ECM Hydrogel for Treating MI February 21, 2012:751–63compared with controls. The average area of these islands of
viable myocardium within the infarct of matrix-injected
hearts (0.05  0.01 mm2) was statistically larger than the
verage area of those within the infarct of saline-injected
Figure 2 Programmed Electrical Stimulation to Assess Potenti
(A) An electrode paces the left ventricle of rat hearts 1 week post-injection. (B) In
pacing is stopped. (D) Sustained ventricular tachycardia (VT) following a single ext
observed difference in the average incidence of VT between saline and myocardial
proarrhythmogenic.earts (0.03  0.01 mm2, matrix, p  0.045) (Fig. 3B).Within these regions of viable myocardium, positive stain-
ing for Connexin 43 was observed (not shown), indicating
the presence of gap junctions. Although quantification of
M2 macrophages within the infarct was not significantly
Arrhythmogenesis
rhythm of rat heart prior to pacing. (C) Return to intrinsic rhythm when burst
ulus. (E) Nonsustained VT following a single extrastimulus. (F) There was no
x groups, demonstrating that the myocardial matrix hydrogel is notal for
trinsic
rastim
matrisignificant between groups (p  0.2) (Fig. 3C), matrix-
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February 21, 2012:751–63 Cardiac ECM Hydrogel for Treating MIinjected hearts did show a significantly higher density of
proliferative cells (saline: 27.6  6.8 per mm2, matrix:
5.1  18 per mm2, p  0.039) (Fig. 3D). Many of the
Ki67 cells had a rounded/oval nuclei shape, which is
ndicative of lymphocytes. Co-staining of Ki67 and tro-
onin revealed that only 1% of Ki67-positive cells were
roliferating cardiomyocytes. Additional slides, co-stained for
i67 and alpha smooth muscle actin, identified that myofibro-
lasts were proliferative within matrix-injected hearts, but were
ot quantified, due to low numbers. We also examined
Figure 3 Histological and Immunohistochemical Assessment
(A) Hematoxylin and eosin staining of matrix-injected infarct demonstrating moder
cardiomyocyte islands were found in the infarct of myocardial matrix–injected hear
infarct of a matrix-injected heart is denoted by the arrow (scale bar  200 m). C
BZ, respectively. (C) There was no significant difference in the number of infiltratin
CD163 cells are labeled red, with a few cells denoted by the arrow points (scale
hearts (*p  0.05). Nuclei are stained blue with Hoechst, and Ki67 cells are lab
(scale bar  50 m). (E) C-kit cells were observed in low numbers within the my
with nuclei in blue (scale bar  10 m).atrix-injected regions for the presence of c-kit cells, which (re progenitor cells that have been shown to differentiate into
yocardial precursors and vascular cells in the heart (40,41).
C-kit cells were observed within the myocardial matrix
caffold (Fig. 3E); however, they were in low numbers.
reservation of cardiac function post-MI. MRI (Figs. 4A
o 4D) was used to measure LV EDV, ESV, and EF at 1
eek post-MI (1 week prior to injection) and 6 weeks
ost-MI (4 weeks post-injection) to evaluate effects of
yocardial matrix injections on cardiac function (Table 2).
s expected, the EF (Fig. 4E) of saline-injected hearts
nonuclear cell infiltration (scale bar  50 m). (B) An increased average area of
pared with saline controls (*p  0.05). An island of viable myocardium in the
troponin T is shown in green with the infarct and border zone denoted by I and
macrophages between groups. Nuclei are stained blue with Hoechst, and
100 m). (D) An increase in proliferative cells were observed in matrix-injected
ed. Co-stained nuclei appear purple, with a couple cells denoted by arrow points
al matrix scaffold. C-kit cells (denoted with arrow points) are labeled in green,ate mo
ts com
ardiac
g M2
bar 
eled r
ocardin  6) significantly declined, whereas both the ESV
758 Singelyn et al. JACC Vol. 59, No. 8, 2012
Cardiac ECM Hydrogel for Treating MI February 21, 2012:751–63(Fig. 4F) and EDV (Fig. 4G) significantly expanded. In
contrast, there was no statistical significance between
EF, ESV, and EDV of myocardial matrix–injected
animals (n  6) (Figs. 4E to 4G) despite injections being
performed 1 week after baseline imaging. When comparing
the percent change in EF, ESV, and EDV between groups,
myocardial matrix–injected animals had an increase in EF
(Fig. 4B), and a relative decrease in percent change in ESV
(Fig. 4I) and EDV (Fig. 4J) compared with controls, although
these were not significant.
Figure 4 MRI Analysis in Rat MI Model
(A) Baseline (1 week post-myocardial infarction [MI], 1 week pre-injection) and (B)
post-injection images of myocardial matrix–injected heart. Scale bar  0.5 cm. (E
(F) end-systolic volume (ESV) (p  0.01) and (G) end-diastolic volume (EDV) (p 
was no statistical significance for EF (p  0.8), ESV (p  0.054), and EDV (p  0
animals had an overall increase in the percent change in EF (§p  0.054) (H), an
pared to saline, although these were not statistically significant. Data are present
MRI DataTable 2 MRI Data
Saline
1 Week Pre-Injection
(1 Week Post-MI)
4 Weeks Post-Injection
(6 Week Post-MI) %
EF, % 58.0 2.4 55.0 4.5* 4
ESV, mm3 137 13 205 25*
EDD, mm3 325 20 451 37*Values are mean  SEM. *p  0.05 compared with baseline.
EDD  end-diastolic dimension; EF  ejection fraction; ESV  end-systolic volume; MRI  magnetic rePercutaneous transendocardial delivery of myocardial
matrix. The liquid myocardial matrix was tested for clinical
feasibility using a MyoStar Intramyocardial Injection device
for transendocardial delivery, a technique that has been
employed for minimally invasive delivery for cellular cardio-
myoplasty (4,5,9). Prior to injection, a unipolar electrome-
chanical map (NOGA) was created to allow for selection of
injection sites. Matrix was prepared as described in the
previous text, loaded into a 1-ml syringe for connection to
the catheter (Fig. 5A), and injections were made via
ks post-injection images of saline-injected heart. (C) Baseline and (D) 4 weeks
ion fraction (EF) of saline controls significantly declined (p  0.04), whereas the
significantly expanded between 1 week and 6 weeks post-MI. By contrast, there
etween time points in the myocardial matrix group. Myocardial matrix–injected
all decrease in the percent change in volume (I and J) between time points com-
the mean  SEM; *p  0.05. MRI  magnetic resonance imaging.
Matrix
e
1 Week Pre-Injection
(1 Week Post-MI)
4 Weeks Post-Injection
(6 Week Post-MI) % Change
.7 62.0 2.0 62.0 3.7 0.7 1.9
2 126 14 157 15 29 14
2 331 27 414 18 30 144 wee
) Eject
0.01)
.06) b
d over
ed asChang
.9 0
49 1
40 1sonance imaging.
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tramyocardial needle-injection catheter. Successful transen-
docardial delivery of liquid myocardial matrix into 25
injection sites (0.2 ml each site) throughout the septal wall
and LV free wall was achieved in the healthy animal, and 15
injections (0.25 ml each site) were achieved in the infarct
and border zone of the infarcted animal, with no sustained
arrhythmias during or after the injection procedures. The
material remained injectable during the approximately 1-h-
long procedures, without premature gelation or clogging of
the catheter. The location of each individual injection was
guided and documented through the use of NOGA map-
ping (Fig. 5B). One to 2 h after injection of myocardial
matrix via transendocardial catheter delivery, the animals
were euthanized and the hearts removed. By gross observation,
there were no signs of pericardial effusion (Fig. 5C). Detection
of the matrix within the LV free wall (Figs. 5D and 5E) and
septal wall of the healthy animal and within the infarct area in
Figure 5 Percutaneous Transendocardial Delivery of Myocardia
(A) Image of myocardial matrix being injected through a MyoStar 27-gauge cathete
healthy animal representing final injection locations, indicated by orange dots. (C)
(D and E) Hematoxylin and eosin (H&E) (left) and diaminobenzidine (right) stainin
dium. Multiple injection locations are shown in D, indicated by arrows. (F) H&E (le
Scale bars  1 mm, 100 m, and 100 m in D, E, and F, respectively.the MI animal (Fig. 5F), confirmed successful delivery into themyocardium, as well as gelation of the matrix in vivo. As with
any intramyocardial injection technique, there is a concern that
the injected material will leak into the ventricle and travel
through the blood stream to other organs. Thus, the lungs,
kidney, brain, liver, and spleen were also examined; no myo-
cardial matrix was observed in any of the satellite organs.
Discussion
This work establishes proof-of-concept for the clinical
feasibility of the recently developed myocardial matrix as an
injectable biomaterial for treating MI through a minimally
invasive approach. Herein, we show that this injectable
scaffold preserves cardiac function in a small animal model.
We further demonstrate that the material can be success-
fully delivered via a percutaneous transendocardial approach
into the ventricular wall in both healthy and infarcted
rix Hydrogel
g a 1-ml Luer lock syringe, attached to the catheter. (A and B) NOGA maps for
heart excision 2 h post-injection, there were no signs of pericardial effusion.
ft ventricular free wall showing gelled myocardial matrix within healthy myocar-
d DAB (right) staining of myocardial matrix scaffold in infarcted myocardium.l Mat
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to eliminate the need for human organ donation, there is
potential concern associated with the immunogenicity of a
xenogeneic material. Previous studies, however, have shown
that xenogeneic decellularized ECMs are biocompatible,
and many have been approved by the Food and Drug
Administration and used successfully in the clinic (42). We
nonetheless examined the local tissue response to the
porcine-derived myocardial matrix hydrogel. The mononu-
clear infiltrate seen here is similar to that seen in previous
studies that show the immune response of decellularized
small intestine submucosa ECM as being comparable to
syngeneic muscle implants, rather than eliciting foreign-
body giant cell formation and encapsulation, indicative of
rejection seen with xenogeneic implantation (43,44). Fur-
thermore, small intestine submucosa ECM implantation
resulted in an increase of cytokines that are known to be
produced by a subset of lymphocytes, Th2 cells, which are
associated with a normal immune response and graft accep-
tance (45,46). Thus, the presence of lymphocytes within the
infarcted tissue of the myocardial matrix–injected hearts
corroborates that the myocardial matrix is able to elicit an
immune response typical of decellularized matrices, and
suggests a potentially positive impact on the infarct envi-
ronment, as the Th2 response that predominates with
decellularized ECMs results in the production of anti-
inflammatory cytokines (43,44). We also found an increase
in proliferating cells, suggesting the matrix affects the
proliferation of cells within the infarct, as was also seen
upon injection of a small intestine submucosa emulsion
(47). Although many of the cells were lymphocytes, we also
co-stained for cardiomyocytes and myofibroblasts. The
heart is known to have limited regenerative capacity, yet
cardiomyocytes have been shown to proliferate in the failing
heart (48). However, only 1% of Ki67 cells were co-
stained for troponin. A small subset of proliferating cells
were also identified as myofibroblasts, which are thought to
be critical in the remodeling process post-MI (49). We
further observed the presence of c-kit cells within the
atrix scaffold; however, they were in low numbers.
A variety of materials have been explored as injectable
herapies for cardiac repair post-MI, and have shown
reserved or improved cardiac function (12–14,50). How-
ver, the recently developed myocardial matrix is naturally
erived from decellularized porcine ventricular tissue and is
herefore uniquely able to offer properties of the native
ardiac ECM. A material that mimics the microenviron-
ent of native ECM structurally and biochemically is
mportant in any tissue engineering application, as it allows
or appropriate cell–matrix interactions (51,52). Natively,
hese interactions are specific for each tissue, with each
CM having its own distinct combination of proteins and
roteoglycans (51,53). The myocardial matrix has been
hown, through gel electrophoresis and glycosaminoglycan
uantification (16), as well as mass spectrometry analysis, to
etain a complexity of ventricular ECM proteins, peptides,nd polysaccharides, making it a cardiac-specific scaffold for
yocardial tissue engineering. This tissue specificity may
rovide benefits over non–tissue-matched decellularized
atrices. For example, a previous study utilizing decellular-
zed urinary bladder matrix as a ventricular patch lead to the
resence of cartilaginous tissue (54), which may have been
he result of non–tissue-specific cues.
Here, we also show an increase in the size of cardiomy-
cyte islands surviving in the infarct area, which, to the best
f our knowledge, has not been previously reported with
ther material injections. Although most cardiomyocytes
ndergo apoptosis or necrosis soon after the induction of
I, and cell death peaks 4 days post-MI, additional waves
f cardiomyocyte death continue for weeks or months (55).
hus, the retained areas of cardiomyocytes suggest that
atrix injection may act to salvage remaining cardiomy-
cytes, or prevent the further necrosis. Furthermore, gap
unctions, identified by Connexin 43 staining, were present
mong these cells, suggesting electrical conductance within
he cardiomyocyte clusters. In addition to local effects on
ndogenous cell types, a cardiac-specific scaffold may also
ave key benefits for transplant cell delivery because the
iochemical cues in the myocardial matrix have been re-
ently shown in vitro to promote enhanced maturation of
uman embryonic stem cell–derived cardiomyocytes (56).
We demonstrate that injection of the myocardial matrix
ydrogel preserves cardiac function post-MI in a rodent
odel; however, the exact mode of action behind the
mprovement for this hydrogel as well as other injectable
aterials has not yet been fully elucidated (57). A recent
tudy in our lab, which showed that an inert nondegradable
ynthetic material did not affect cardiac function post-MI,
uggests that biological cues or cell infiltration as a result of
aterial degradation may play important roles in preserv-
ng/improving LV function (58). In this study, we show the
yocardial matrix results in an influx of cells typical of
ecellularized ECM materials, which includes lymphocytes.
s stated in previous text, a Th2 response, as seen with
ecellularized ECMs, results in the production of anti-
nflammatory cytokines, including interleukin (IL)-10
43,44). IL-10 has been shown to inhibit LV remodeling
nd improve function post-MI (59), and therefore may also
e a potential mode of action here. We have previously
hown that the myocardial specific biochemical cues in the
yocardial matrix promote maturation of human embryonic
tem cell derived cardiomyocytes in vitro (56). In this study,
e saw an increase in the size of surviving islands of viable
yocardium within the infarct. This result may be due to
he presence of myocardial specific cues in the myocardial
atrix; however, the material on its own does not appear to
esult in significant regeneration because we only saw low
umbers of c-kit cells within the scaffold. Although a
material-alone therapy would facilitate translation, a com-
bination therapy may be needed to promote regeneration.
A safety issue that has arisen with intramyocardial injec-
tions is the potential for arrhythmogenesis. Although many
761JACC Vol. 59, No. 8, 2012 Singelyn et al.
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in rodent models, none have directly assessed whether
injection of these materials increases arrhythmias. We
therefore performed programmed electrical stimulation
studies 1 week post-injection in the rat model as well as
monitored the ECG up to 2 h post-injection in the porcine
model. We did not observe an increase in incidences of
arrhythmia with injection of the myocardial matrix hydro-
gel. Our results, along with 2 recent reports of material
injections in porcine models (through intracoronary infu-
sion [15] and intramyocardial injection [60]), suggest that
material delivery into the infarct area does not lead to
induced arrhythmogenesis. However, material degradation
and scar maturation over time may lead to electrophysio-
logical changes, and therefore, it will be critical to assess
multiple time points for a given material in a large animal
model prior to clinical translation.
Several materials investigated for injectable therapy, in-
cluding fibrin glue (13,21), collagen (14), chitosan (61),
Matrigel (62), and hyaluronic acid (63) have demonstrated
preserved or improved cardiac function, yet may not trans-
late to catheter delivery in the heart, which would limit their
relevance for minimally invasive treatment in humans. For
an injectable material to be clinically relevant for percuta-
neous delivery in the heart, the material must remain liquid,
with an appropriate viscosity for delivery of multiple injec-
tions through a catheter, and convert to a gel once it is
within the myocardial tissue. Although several materials
have shown promising results in small animals, few have
actually been translated to percutaneous delivery in large
animals. Recently, alginate (15) was delivered through
intracoronary injection in large animals. However, endocar-
dial delivery, commonly used for cellular cardiomyoplasty
(4,5,9,15,64,65), is considered to be the preferred method of
catheter delivery in terms of retention (66–68), because it
allows for direct intramyocardial delivery and does not
require access to the coronary vessels. In addition, the
guarantee of migration into the myocardium is uncertain
with intracoronary delivery, and there is a risk of microem-
bolism (69). Here, we show that the myocardial matrix
hydrogel preserves cardiac function post-MI in a rat model,
and also demonstrate that it is deliverable via catheter in a
porcine model. The myocardial matrix was successfully
injected via a percutaneous, transendocardial approach in
both healthy and infarcted porcine myocardium without
clogging the catheter. It should, however, be noted that
some leakage of injectate into the ventricle is known to
occur with transendocardial delivery (5,31). Any myocardial
matrix that leaks into the ventricle would likely be rapidly
diluted in the blood, thereby preventing gelation. We
confirmed through histological analysis that the myocardial
matrix formed a hydrogel within the porcine myocardial
tissue without measurable embolization in other organs. It
is, however, possible that a small amount of material was
present in other organs and below our detection limit.Study limitations. First, injections were performed 2
weeks post-MI, an entire week after the baseline MRI
analysis. Because of this delay between baseline measure-
ments and treatment injection, the LV volume likely con-
tinued to increase prior to injection, which is indicated by
the data (Fig. 4). Therefore, it is unknown if this decrease
would occur if injections had been performed immediately
post baseline imaging. Second, LV remodeling is well
underway at the injection time point of 2 weeks post-MI,
and injection of the myocardial matrix shortly after MI, at
which time the native ECM has been recently degraded,
may have enhanced effects. However, we chose to inject at
a later time point as it is more clinically relevant than
injection immediately post-MI when there is a significant
risk of ventricular rupture. Last, although we examined
catheter delivery in a large animal, the majority of this study
is in a rat myocardial infarction model. Inherent limitations
with this model include the inability to precisely control
injections and, therefore, the inability to homogenously
cover the entire infarct area. Examining functional changes
in a large animal MI model will be critical prior to clinical
translation.
Conclusions
Although a variety of materials have shown success in small
animal models (12–14,50), the myocardial matrix not only
preserves cardiac function in a rat model, without inducing
arrythmias, but also shows initial translation to large ani-
mals. Specifically, we have shown clinical feasibility of the
myocardial matrix for minimally invasive delivery, by dem-
onstrating transendocardial catheter delivery and retention
within the myocardium. The myocardial matrix is the first
material to be designed as a tissue-specific, injectable
scaffold for cardiac tissue engineering, and is to our knowl-
edge the first in situ gelling material to be injected via
percutaneous transendocardial delivery. Our results warrant
further study of this material in a large animal MI model
and demonstrate the potential of this technology for treating
patients with MI.
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